Literature DB >> 15179764

[Identification of sentinel lymph nodes in thyroid carcinoma].

R Dzodic1, I Marković, M Inić, N Jokić, M Zegarac, I Djuricic, Z Milovanović, G Pupic, N Jovanović.   

Abstract

Sentinel lymph node (SLN) was defined as the first lymph node that the tumor would drain to, within that tumors regional lymphatic basin. In 1998, Kelemen and coworkers have published the first results on SLN lymphonodectomy in thyroid carcinomas. Different methods have been used in a goal of lymphatic mapping (application of vital blue dye and/or radiocolloid). In a period from 2001 to 2003 we have performed SLN biopsy in 64 patients with thyroid tumors. There were 12 cases of thyroid carcinoma. SLN identification rate was 73.44%. We found no false positive or negative results on definitive histopathology. The impact of lymph node metastases in differentiated thyroid carcinoma is still controversial. The management of cervical lymph nodes varies from berry picking to modified radical neck dissection. There is a significant disproportion in percentage of pre and intraoperatively enlarged lymph nodes (27-45%) and histologically confirmed lymph node metastases (80-90%) in papillary thyroid carcinoma. In the current literature the average rate of SLN identification is 91% (66-100%) and when identified, the SLN accurately predicts the disease status of the neck in most patients (80-100%). The SLN biopsy for thyroid carcinoma is good and feasible technique for estimating the cervical lymph node status.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15179764     DOI: 10.2298/aci0303103d

Source DB:  PubMed          Journal:  Acta Chir Iugosl        ISSN: 0354-950X


  1 in total

1.  SPECT/CT sentinel lymph node identification in papillary thyroid cancer: lymphatic staging and surgical management improvement.

Authors:  Amparo Garcia-Burillo; Isabel Roca Bielsa; Oscar Gonzalez; Carles Zafon; Monica Sabate; Josep Castellvi; Xavier Serres; Carmela Iglesias; Ramon Vilallonga; Enric Caubet; Jose Manuel Fort; Jordi Mesa; Manuel Armengol; Joan Castell-Conesa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-02       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.